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Background
Prenatal screening for IDA and routine iron supplementation 
may allow clinicians to diagnose and preemptively treat iron 
deficiency and IDA in pregnant women, leading to a decreased 
risk of  future negative health outcomes. However, there is a lack 
of  one consistent set of  guidelines that can be applied safely to 
all populations globally. These guidelines will let clinicians deliver 
the most efficient care to their patients. One such effort was made 
by the United States Preventive Services Task Force (USPSTF), 
which last reviewed evidence on prenatal screening for IDA 
in 2006 and recommended routine screening on the basis 
of  fair‑quality evidence. According to the USPTF, although 
there is insufficient evidence for screening asymptomatic or 
treating nonanemic asymptomatic pregnant women, treatment 
of  asymptomatic IDA has moderate health benefits. This 
summary reports the evidence for routine screening and iron 
supplementation for IDA in nonsymptomatic pregnant women.
How was the Study Done?
Researchers from the USPSTF conducted a systematic review 
and meta‑analysis of  studies reporting routine screening and 
iron supplementation for asymptomatic (anemic and nonanemic) 
women and the intervention’s effect on any health outcomes for 
women and infants.
The review included randomized controlled trials, nonrandomized, 
controlled trials and cohort studies including asymptomatic 
pregnant women receiving screening or supplementation for 
IDA, and the studies were in English. When good‑ and fair‑quality 
studies were available, poor‑quality studies were excluded as were 
studies only published with abstracts or without original data. 
The review focused on studies using iron supplementation and 
treatment regimens commonly used in clinical practice in the 
United States and those conducted in countries with “high” or 
“very high” human development based on the United Nations’s 
Human Development Index.
How was Quality of Evidence Assessed?
Study quality was assessed by the two reviewers who used 
predefined criteria set by the USPSTF, which rates study 
quality as good, fair, or poor. Discrepancies were addressed by 
consensus.
Can routine screening and iron supplementation for iron 
deficiency anemia in nonsymptomatic pregnant women 
improve maternal and infant health outcomes?
Anoosh Moin1, Zohra S. Lassi2
1Department of Paediatrics, Aga Khan University, Karachi, Pakistan, 2Department of Obstetrics and Gynecology, Australian 
Research Centre for Health of Women and Babies, Robinson Research Institute, School of Paediatrics and Reproductive Health, 
The University of Adelaide, Adelaide, Australia
Evidence Based Summary






Address for correspondence: Dr. Zohra Lassi, 
Australian Research Centre for Health of Women and Babies, 
Robinson Research Institute, School of Paediatrics and 
Reproductive Health, The University of Adelaide, Adelaide, 
Australia. E‑mail: Zohra.lassi@adelaide.edu.au. 
Dr. Anoosh Moin,  Department of Paediatrics, 
Aga Khan University, Karachi, Pakistan. 
E‑mail: Anoosh.moin@gmail.com
CliniCal SCenario
Pregnant women have an increased need for iron that might not be met with diet alone. Due to physiologic anemia and population 
differences, no set criteria for defining iron deficiency anemia (IDA) are available globally. Serum ferritin and transferrin levels 
are often used to guide therapy by clinicians. Studies have reported an association  between poor iron status and negative health 
outcomes such as low birth weight, premature birth, and perinatal death for women and their infants, although the evidence is weak.
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What did the Study Find?
After conducting a thorough search, researchers from the USPSTF 
selected 12 trials that compared the effects of  routine prenatal iron 
supplementation versus no supplementation. No trials reporting on 
the benefits or harm of  routine screening on pregnant, maternal, 
or infant health outcomes were found. Evidence from new trials 
supports the previous findings of  routine supplementation 
improving maternal IDA and other blood indices. However, 
there is still insubstantial evidence for the effect of  routine 
iron supplementation or screening on maternal or infant health 
outcomes as reported in Table 1. This means that the current 
evidence supports the previous USPTF recommendations of  
routine prenatal iron supplementation. Studies included were of  
good and fair quality; however, due to low number of  trials, there is 
a lack of  generalizability, no consistent amount of  iron dose used, 
and clinical outcomes mostly reported as ad hoc events.
Implications for Clinical Practice
 Evidence supports routine supplementation in terms of  maternal 
hematologic health but does not have any impact on maternal and 
infant clinical health outcomes. For the second question, evidence 
was not strong enough to support or oppose the effect of  routine 
screening on anemic and nonanemic women in terms of  future 
health benefit(s) or harm(s) for the involved woman or infant. For 
physicians, the message is that routine supplementation of  iron 
during pregnancy does improve hematologic markers in women 
reducing future risk of  IDA, so it should be continued. However, 
routine screening for IDA in asymptomatic women may or may 
not be conducted since there is still a lack of  sufficient evidence 
to develop a recommendation for this procedure.
Implications for Research
The previous USPTF report identified certain research gaps 
that included whether routine iron supplementation and IDA 
screening impacted future clinical outcomes of  women and their 
children as well as whether routine IDA screening should be 
implemented in asymptomatic women. This report, albeit able 
to corroborate the findings for routine iron supplementation, 
found inadequate evidence for routine IDA screening and 
did not address whether routine IDA screening will impact 
the hematologic indices of  asymptomatic women. These gaps 
need to be filled with strong long‑term clinical trials needed to 
evaluate the effect of  screening and routine iron supplementation 
on maternal and infant short‑ and long‑term health outcomes. 
Trials need to be conducted on a large scale in high‑, middle‑, 
and low‑income countries that focus on certain regimens, stratify 
populations based on risk factors, and are powered to report 
clinical outcomes.
Conclusion
Trials support the use of  routine iron supplementation in anemic 
and nonanemic asymptomatic pregnant women; however, there 
is a lack of  evidence for or against routine screening in this 
population.
This evidence‑based summary is based on Cantor 2015.[1]
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Table 1: Summary of pooled results
Intervention Outcome Effect estimate Heterogeneity Quality
Routine iron supplementation versus 
no supplementation or placebo
Preterm delivery (defined as 
delivery at <37 weeks)
#RR 0.88 (95% *CI: 0.55, 1.42)
Two studies, n=1,010 χ² P 0.38; I I
2 0% Fair
Low birth weight (defined mostly 
as <2500 g)
RR 1.10 (95% CI: 0.54, 2.25)
Three studies, n=688 χ² P 0.45; I I
2 0% Fair
IDA (defined as hemoglobin level 
<110 g/L and serum ferritin level 
<27 pmol/L or <44.9 pmol/L)
RR 0.29 (95% CI: 0.17, 0.49)
Four studies, n=762 χ² P 0.55; I I
2 0% Fair
Iron deficiency (defined as 
serum ferritin level <27 pmol/L, 
<33.7 pmol/L, or <44.9 pmol/L)
RR 0.53 (95% CI: 0.33, 0.84)
Three studies, n=510 χ² P 0.20; I I
2 40% Fair
*CI: Confidence interval; #RR: Risk ratio
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